{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/etodolac-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716225",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716225_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716226",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716226_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"aciclovir\" outputclass=\"int-drug\">aciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  aciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716227",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716227_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"adefovir\" outputclass=\"int-drug\">adefovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  adefovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adefovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716228",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716228_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"alendronic acid\" outputclass=\"int-drug\">alendronic acid</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of gastrointestinal irritation when given with   alendronic acid .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alendronic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716229",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716229_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716230",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716230_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716231",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716231_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amikacin\" outputclass=\"int-drug\">amikacin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amikacin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amikacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716232",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716232_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716232_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716233",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716233_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amitriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716234",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716234_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amphotericin\" outputclass=\"int-drug\">amphotericin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amphotericin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716235",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716235_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  anagrelide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716236",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716236_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716237",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716237_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716238",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716238_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  aspirin  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716239",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716239_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  azilsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716240",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716240_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bacitracin\" outputclass=\"int-drug\">bacitracin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bacitracin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacitracin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716241",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716241_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">beclometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   beclometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716242",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716242_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716242_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   bendroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716243",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716243_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">betamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   betamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716244",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716244_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bevacizumab  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716245",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716245_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716246",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716246_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"budesonide\" outputclass=\"int-drug\">budesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   budesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716247",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716247_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716248",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716248_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  candesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716249",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716249_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cangrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716250",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716250_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"capreomycin\" outputclass=\"int-drug\">capreomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  capreomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capreomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716251",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716251_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716252",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716252_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716253",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716253_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  carboplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716254",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716254_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefaclor\" outputclass=\"int-drug\">cefaclor</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefaclor  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefaclor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716255",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716255_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefadroxil\" outputclass=\"int-drug\">cefadroxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefadroxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefadroxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716256",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716256_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefalexin\" outputclass=\"int-drug\">cefalexin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefalexin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefalexin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716257",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716257_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefixime\" outputclass=\"int-drug\">cefixime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefixime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefixime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716258",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716258_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefotaxime\" outputclass=\"int-drug\">cefotaxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefotaxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefotaxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716259",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716259_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefradine\" outputclass=\"int-drug\">cefradine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefradine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716260",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716260_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftaroline\" outputclass=\"int-drug\">ceftaroline</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftaroline  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftaroline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716261",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716261_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftazidime\" outputclass=\"int-drug\">ceftazidime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftazidime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftazidime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716262",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716262_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftobiprole\" outputclass=\"int-drug\">ceftobiprole</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftobiprole  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftobiprole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716263",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716263_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftolozane\" outputclass=\"int-drug\">ceftolozane</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftolozane  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftolozane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716264",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716264_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftriaxone\" outputclass=\"int-drug\">ceftriaxone</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftriaxone  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftriaxone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716265",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716265_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefuroxime\" outputclass=\"int-drug\">cefuroxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefuroxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefuroxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716266",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716266_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716266_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   chlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716267",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716267_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716267_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   chlortalidone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716268",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716268_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"ciclesonide\" outputclass=\"int-drug\">ciclesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   ciclesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716269",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716269_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ciclosporin  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716269_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716270",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716270_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cidofovir\" outputclass=\"int-drug\">cidofovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cidofovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cidofovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716271",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716271_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cilostazol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716272",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716272_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ciprofloxacin\" outputclass=\"int-drug\">ciprofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   ciprofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716273",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716273_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cisplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716274",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716274_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  citalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716274_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  citalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716275",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716275_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  clomipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716276",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716276_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  clopidogrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716277",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716277_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"colistimethate\" outputclass=\"int-drug\">Colistimethate</ph> <ph outputclass=\"int-substanceQualifier\">(particularly intravenous)</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of nephrotoxicity when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Colistimethate   (particularly intravenous)   potentially   increases   the risk of nephrotoxicity when given with   etodolac .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colistimethate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716278",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716278_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716279",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716279_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">dalteparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dalteparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716279_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dalteparin   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716280",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716280_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716281",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716281_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dapoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716281_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  dapoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716282",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716282_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"daptomycin\" outputclass=\"int-drug\">daptomycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of renal impairment when given with   daptomycin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716283",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716283_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  darbepoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716284",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716284_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dasatinib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716285",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716285_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">deferasirox</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of gastrointestinal bleeding when given with   deferasirox .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716286",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716286_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716287",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716287_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716288",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716288_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">dexamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   dexamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716289",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716289_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dipyridamole  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716290",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716290_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dosulepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716291",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716291_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  doxepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716292",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716292_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716293",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716293_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716293_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  duloxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716294",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716294_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716295",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716295_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716296",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716296_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">enoxaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  enoxaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716296_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Enoxaparin   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716297",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716297_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716297_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716298",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716298_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716299",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716299_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716300",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716300_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716301",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716301_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoprostenol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716302",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716302_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  eprosartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716303",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716303_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">eptifibatide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  eptifibatide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716304",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716304_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">Erlotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Erlotinib   is predicted to   increase   the risk of gastrointestinal perforation when given with   etodolac .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716305",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716305_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  escitalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716305_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  escitalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716306",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716306_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">fludrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   fludrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716307",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716307_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  fluoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716307_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  fluoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716308",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716308_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fluticasone\" outputclass=\"int-drug\">fluticasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   fluticasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluticasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716309",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716309_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  fluvoxamine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716309_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  fluvoxamine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716310",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716310_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716311",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716311_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"foscarnet\" outputclass=\"int-drug\">foscarnet</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  foscarnet  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Foscarnet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716312",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716312_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716313",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716313_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716314",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716314_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716315",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716315_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"gentamicin\" outputclass=\"int-drug\">gentamicin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  gentamicin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gentamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716316",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716316_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"heparin (unfractionated)\" outputclass=\"int-drug\">heparin (unfractionated)</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  heparin (unfractionated)  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716316_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin (unfractionated)\" outputclass=\"int-drug\">Heparin (unfractionated)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Heparin (unfractionated)   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin (unfractionated)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716317",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716317_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716317_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   hydrochlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716318",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716318_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">hydrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   hydrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716319",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716319_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716319_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   hydroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716320",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716320_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"ibandronic acid\" outputclass=\"int-drug\">ibandronic acid</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of gastrointestinal irritation when given with   ibandronic acid .  Manufacturer advises caution and monitor side effects .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibandronic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716321",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716321_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ibrutinib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716322",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716322_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ifosfamide  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716323",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716323_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  iloprost  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  imipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716326_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   indapamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  inotersen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  irbesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"levofloxacin\" outputclass=\"int-drug\">levofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   levofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  losartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  methotrexate  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716333_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of toxicity when given with</ph> <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of toxicity when given with   methotrexate .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">methylprednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   methylprednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716335_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   metolazone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   (high-dose)   is predicted to   decrease   the efficacy of   mifamurtide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"mometasone\" outputclass=\"int-drug\">mometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   mometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   moxifloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"neomycin\" outputclass=\"int-drug\">neomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  neomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">Nicorandil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicorandil   is predicted to   increase   the risk of gastrointestinal perforation when given with   etodolac .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  nortriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ofloxacin\" outputclass=\"int-drug\">ofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   ofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  olmesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">Omega-3-acid ethyl esters</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Omega-3-acid ethyl esters   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  oxaliplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  paroxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716347_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  paroxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  pemetrexed  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716348_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   is predicted to   increase   the exposure to   pemetrexed .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"penicillamine\" outputclass=\"int-drug\">penicillamine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  penicillamine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Penicillamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  pentamidine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"polymyxins\" outputclass=\"int-drug\">polymyxins</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  polymyxins  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Polymyxins</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  prasugrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">prednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   prednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  regorafenib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  sertraline  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716363_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  sertraline  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"sodium clodronate\" outputclass=\"int-drug\">sodium clodronate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of renal impairment when given with   sodium clodronate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium clodronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716366_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"streptomycin\" outputclass=\"int-drug\">streptomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  streptomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  streptozocin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sulfinpyrazone\" outputclass=\"int-drug\">sulfinpyrazone</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  sulfinpyrazone  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfinpyrazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tacrolimus  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716371_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"telavancin\" outputclass=\"int-drug\">telavancin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  telavancin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telavancin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  telmisartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tenofovir disoproxil\" outputclass=\"int-drug\">tenofovir disoproxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tenofovir disoproxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir disoproxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ticagrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">tinzaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tinzaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716377_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">tirofiban</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tirofiban  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tobramycin\" outputclass=\"int-drug\">tobramycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tobramycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tobramycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  trastuzumab emtansine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">triamcinolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   triamcinolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716385_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  trimethoprim  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716386_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  trimethoprim  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716386_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  etodolac  and  trimethoprim  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  trimipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"valaciclovir\" outputclass=\"int-drug\">valaciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  valaciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valaciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  valganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  valsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"vancomycin\" outputclass=\"int-drug\">vancomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  vancomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vancomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  venlafaxine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  vortioxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   is predicted to   increase   the risk of bleeding events when given with   etodolac .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716396_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   xipamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  zidovudine  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716397_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">Zidovudine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of haematological toxicity when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Zidovudine   increases   the risk of haematological toxicity when given with   etodolac .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1557280716398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"zoledronic acid\" outputclass=\"int-drug\">zoledronic acid</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  zoledronic acid  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zoledronic acid</title>"
					}
				}
			],
			"hasSearchLabel": " Etodolac  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/etodolac-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Etodolac </title>"
			},
			"rdfs:label": "etodolac"
		}
	]
}